Cargando…
Health management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma
The goal of the 1-year observational, multicentre, open-label study reported here was to identify factors influencing adherence to high-dose interferon alfa-2b adjuvant therapy in patients at high risk of recurrence following surgical excision of malignant melanoma. The study was carried out in 23 t...
Autores principales: | Levesque, N., Mitchinson, K., Lawrie, D., Fedorak, L., MacDonald, D., Normand, C., Pouliot, J.F. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Multimed Inc.
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2259435/ https://www.ncbi.nlm.nih.gov/pubmed/18317583 |
Ejemplares similares
-
Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma
por: Jia, Dong-Dong, et al.
Publicado: (2021) -
High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma
por: Silk, Ann W., et al.
Publicado: (2020) -
Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?
por: Hauschild, A.
Publicado: (2009) -
Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma
por: Salans, Mia, et al.
Publicado: (2021) -
Educational level-dependent melanoma awareness in a high-risk population in Switzerland
por: Mueller, Alina Miriam, et al.
Publicado: (2023)